OSCR
Oscar Health, Inc.
OSCR has the edge over PRCT overall, supported by stronger fundamentals and stronger modeled upside.
PRCT
PROCEPT BioRobotics Corporation
PRCT has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PRCT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
PRCT's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
PRCT PE Valuation
PRCT has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
PRCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PRCT's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over PRCT on earnings quality, reporting a profit while its opponent remains loss making.
PRCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.03 | -$0.51 |
| Q2 2026 | -$1.95 | -$0.41 |
| Q1 2026 | -$1.83 | -$0.14 |
| Q4 2025 | -$1.72 | +$0.03 |
| Q3 2025 | -$1.52 | +$0.43 |
| Q2 2025 | -$1.54 | +$0.52 |
| Q1 2025 | -$1.69 | +$0.43 |
| Q4 2024 | -$1.75 | +$0.49 |
PRCT lost $2.03 per share over the past year, a bigger loss than the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over PRCT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over PRCT on profitability, with a higher operating margin.
PRCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $98.3M | +18% |
| Q2 2026 | $94.5M | +19% |
| Q1 2026 | $83.1M | +20% |
| Q4 2025 | $76.4M | +12% |
| Q3 2025 | $83.3M | +43% |
| Q2 2025 | $79.2M | +48% |
| Q1 2025 | $69.2M | +55% |
| Q4 2024 | $68.2M | +57% |
PRCT's revenue has grown year over year every quarter since early 2021: $98M last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -28% | 0 points |
| Q2 2026 | -29% | -1 points |
| Q1 2026 | -39% | +0.5 points |
| Q4 2025 | -41% | -12 points |
| Q3 2025 | -28% | +11 points |
| Q2 2025 | -28% | +22 points |
| Q1 2025 | -40% | +22 points |
| Q4 2024 | -29% | +39 points |
PRCT's operating margin was −28% last quarter, about level with the same quarter a year ago, near the top of its range since 2020.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over PRCT on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.7M | -$149K |
| Q2 2026 | -$22.2M | -$4.4M |
| Q1 2026 | -$41M | -$22.2M |
| Q4 2025 | -$12.2M | +$21.4M |
| Q3 2025 | -$9.5M | +$9.5M |
| Q2 2025 | -$17.8M | -$1.1M |
| Q1 2025 | -$18.8M | +$15.4M |
| Q4 2024 | -$33.6M | -$57K |
PRCT has burned cash in almost every quarter: −$85M over the past year, against −$80M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PRCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +259K shares |
| 1 year | +2.9% | +1.6M shares |
| 3 years | +19% | +9M shares |
| 5 years | +39% | +16.1M shares |
PRCT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
PRCT Net Leverage
PRCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PRCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.6 | Neutral |
| Stochastic | 60.7 | Neutral |
PRCT's weekly RSI is 55 (neutral) and its Stochastic is 61 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PRCT PE vs Healthcare Sector
PRCT has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over PRCT on trend strength, trading above more of its moving averages.
PRCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.2 | 22% above |
| 20 week MA | $19.9 | 18% above |
| 50 week MA | $24.5 | 3.8% below |
| 100 week MA | $39.0 | 40% below |
| 200 week MA | $44.3 | 47% below |
PRCT has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 47% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PRCT on returns for 2026, with the stronger performance.
PRCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $40.0 | $27.0 | -32% |
| 2022 | $27.0 | $40.9 | +51% |
| 2023 | $40.9 | $41.9 | +2.4% |
| 2024 | $41.9 | $82.0 | +96% |
| 2025 | $82.0 | $32.4 | -60% |
| 2026 YTD | $32.4 | $23.5 | -27% |
PRCT has finished higher in three of the last five years, two of them by more than 50%. It's down 27% so far in 2026.